A pivotal clinical trial of NTLA-2001 in transthyretin amyloidosis with polyneuropathy (ATTRv-PN)
Latest Information Update: 09 Jan 2024
At a glance
- Drugs NTLA-2001 (Primary)
- Indications Transthyretin-related hereditary amyloidosis
- Focus Registrational; Therapeutic Use
- Sponsors Intellia Therapeutics
- 04 Jan 2024 According to Intellia Therapeutics media release, the company anticipates to prepare for this trial in 2024
- 01 Jul 2021 New trial record